Quantcast

Latest Cardiac surgery Stories

2014-10-20 23:05:56

Allegheny General Hospital, part of the Allegheny Health Network, is offering a new, minimally-invasive procedure that enables physicians to repair a damaged mitral valve as the heart continues to beat. The MitraClip system, developed by Abbott Vascular, is designed to treat degenerative mitral regurgitation (MR), a progressive and life-threatening condition in which the heart’s mitral valve leaflets fail to close tightly, allowing blood to flow backward from the heart’s left ventricle...

2014-10-20 16:26:56

First Aortic Valve With Removable Stent Provides Performance Similar to Native Valve With the Ease of Implanted Stented Valve AUSTIN, Texas, Oct. 20, 2014 /PRNewswire/ -- On Oct. 16, 2014, surgeons with Cardiothoracic and Vascular Surgeons became the first in Texas to implant the Solo Smart((TM)) Aortic Pericardial Heart Valve. Faraz Kerendi, M.D. and Stephen J. Dewan M.D., cardiothoracic surgeons at Cardiothoracic and Vascular Surgeons, performed the procedure at Heart Hospital of...

2014-10-14 08:30:58

MONMOUTH JUNCTION, N.J., Oct. 14, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood purification therapy to prevent or treat life-threatening illnesses in the intensive care unit and in cardiac surgery, provides a preliminary update on Q3 2014 operating and business progress as well as an update on its planned up-listing efforts....

2014-10-09 08:27:14

NASDAQ: NVCNTSX: NVC VANCOUVER, Oct. 9, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara(TM) transcatheter mitral valve. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial being conducted to...

2014-10-08 12:28:07

"Recapturable" heart valve tested as alternative to open heart surgery ANN ARBOR, Mich., Oct. 8, 2014 /PRNewswire-USNewswire/ -- The University of Michigan Frankel Cardiovascular Center is one of the first hospitals in the country to implant Medtronic's new investigational device during transcatheter aortic valve replacement (TAVR). The CoreValve(®) Evolut((TM)) R System is being studied in patients with severe aortic stenosis who are considered at high or extreme risk for open...

2014-10-07 08:29:21

Funds to Be Used to Extend Commercial Efforts, Capitalize on Promising Patient Data KIRKLAND, Wash., Oct. 7, 2014 /PRNewswire/ -- Cardiac Dimensions(®) today announced the addition of $8.5 million to its previously announced financing. Arboretum Ventures, a Michigan-based venture capital firm specializing in the healthcare sector, joined an international syndicate of institutional investors from Australia, the U.S. and Canada that includes M.H. Carnegie & Co. and Lumira Capital....

2014-09-30 23:04:54

Icahn School of Medicine at Mount Sinai research findings show there was no significant difference in 15-year survival or stroke rates in patients aged between 50 and 69 years who had aortic valve replacement with bioprosthetic valves compared with mechanical valves. New York, NY (PRWEB) September 30, 2014 New Icahn School of Medicine at Mount Sinai research findings published in the October 1 issue of JAMA show there was no significant difference in 15-year survival or stroke rates in...

2014-09-29 12:30:22

JENA, Germany, September 29, 2014 /PRNewswire/ -- Occlutech, a leading innovator of products to treat structural heart disease today announced that it has obtained a European CE Mark approval for its dedicated Paravalvular Leak Closure Device, (PLD). The implant is the world's first, specifically designed device indicated for the minimally invasive closure of leaks occurring around artificial aortic and mitral valves. Tor Peters, CEO of the Occlutech Group, commented:...

2014-09-24 08:27:29

CHICAGO, September 24, 2014 /PRNewswire/ -- New valves may grow with patients and may have lower rejection rates Researchers have found a way to take a pediatric patient's skin cells, reprogram the skin cells to function as heart valvular cells, and then use the cells as part of a tissue-engineered pulmonary valve. A proof of concept study published in the September 2014 issue of The Annals of Thoracic Surgery provides more detail on this scientific...

2014-09-23 16:27:38

Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval MARLBOROUGH, Mass., Sept. 23, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus(TM) Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic...


Latest Cardiac surgery Reference Libraries

0_886104d1c1c698f3a531e056704457d5
2010-10-14 16:46:25

The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...

More Articles (1 articles) »
Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.